D Mahadevan

Summary

Affiliation: University of Arizona
Country: USA

Publications

  1. ncbi request reprint Tumor-stroma interactions in pancreatic ductal adenocarcinoma
    Daruka Mahadevan
    Hematology Oncology, The University of Arizona Cancer Center, 1515 North Campbell Avenue, Tucson, AZ 58724, USA
    Mol Cancer Ther 6:1186-97. 2007
  2. doi request reprint Phase I trial of AEG35156 an antisense oligonucleotide to XIAP plus gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma
    Daruka Mahadevan
    Arizona Cancer Center, Tucson, AZ 85724, USA
    Am J Clin Oncol 36:239-43. 2013
  3. doi request reprint Aurora kinase targeted therapeutics in oncology: past, present and future
    Daruka Mahadevan
    Arizona Cancer Center, Tucson, AZ, 85724, USA 1 520 626 0191 1 520 626 2255
    Expert Opin Drug Discov 2:1011-26. 2007
  4. pmc Phase 2 trial of combined cisplatin, etoposide, gemcitabine, and methylprednisolone (PEGS) in peripheral T-cell non-Hodgkin lymphoma: Southwest Oncology Group Study S0350
    Daruka Mahadevan
    Section of Hematology, University of Arizona Arizona Cancer Center, Tucson, Arizona 85724, USA
    Cancer 119:371-9. 2013
  5. doi request reprint Aurora A inhibitor (MLN8237) plus vincristine plus rituximab is synthetic lethal and a potential curative therapy in aggressive B-cell non-Hodgkin lymphoma
    Daruka Mahadevan
    Arizona Cancer Center, The University of Arizona, Tucson, Arizona 85724, USA
    Clin Cancer Res 18:2210-9. 2012
  6. pmc The c-Met receptor tyrosine kinase inhibitor MP470 radiosensitizes glioblastoma cells
    James W Welsh
    Departmentr of Radiation Oncology, The University of Texas M, d, Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, USA
    Radiat Oncol 4:69. 2009
  7. pmc MP470, a novel receptor tyrosine kinase inhibitor, in combination with Erlotinib inhibits the HER family/PI3K/Akt pathway and tumor growth in prostate cancer
    Wenqing Qi
    Arizona Cancer Center, The University of Arizona, Tucson, AZ 85724, USA
    BMC Cancer 9:142. 2009
  8. ncbi request reprint A novel tyrosine kinase switch is a mechanism of imatinib resistance in gastrointestinal stromal tumors
    D Mahadevan
    Arizona Cancer Center, Tucson, AZ 85724, USA
    Oncogene 26:3909-19. 2007
  9. ncbi request reprint Transcriptosome and serum cytokine profiling of an atypical case of myelodysplastic syndrome with progression to acute myelogenous leukemia
    Daruka Mahadevan
    University of Arizona Cancer Center, Tucson, Arizona 85724, USA
    Am J Hematol 81:779-86. 2006
  10. doi request reprint Phase I study of fixed dose gemcitabine plus epirubicin in patients with advanced solid malignancies
    Daruka Mahadevan
    Arizona Cancer Center, University of Arizona Health Sciences Center, Tucson, Arizona, USA
    Am J Clin Oncol 32:607-11. 2009

Collaborators

Detail Information

Publications37

  1. ncbi request reprint Tumor-stroma interactions in pancreatic ductal adenocarcinoma
    Daruka Mahadevan
    Hematology Oncology, The University of Arizona Cancer Center, 1515 North Campbell Avenue, Tucson, AZ 58724, USA
    Mol Cancer Ther 6:1186-97. 2007
    ..This review summarizes our current understanding of the mechanisms that potentially drive the DR in PDA and future possibilities for therapeutic targeting of this critical process...
  2. doi request reprint Phase I trial of AEG35156 an antisense oligonucleotide to XIAP plus gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma
    Daruka Mahadevan
    Arizona Cancer Center, Tucson, AZ 85724, USA
    Am J Clin Oncol 36:239-43. 2013
    ..A phase I study was conducted to establish the maximum-tolerated dose, safety, and antitumor activity of AEG35156 plus gemcitabine in metastatic PDA...
  3. doi request reprint Aurora kinase targeted therapeutics in oncology: past, present and future
    Daruka Mahadevan
    Arizona Cancer Center, Tucson, AZ, 85724, USA 1 520 626 0191 1 520 626 2255
    Expert Opin Drug Discov 2:1011-26. 2007
    ..At present, Aurora inhibitors are being evaluated in Phase I trials. The future holds promise for rational combinations in both solid and hematological malignancies...
  4. pmc Phase 2 trial of combined cisplatin, etoposide, gemcitabine, and methylprednisolone (PEGS) in peripheral T-cell non-Hodgkin lymphoma: Southwest Oncology Group Study S0350
    Daruka Mahadevan
    Section of Hematology, University of Arizona Arizona Cancer Center, Tucson, Arizona 85724, USA
    Cancer 119:371-9. 2013
    ..Gemcitabine was included because of its excellent single-agent activity in PTCL...
  5. doi request reprint Aurora A inhibitor (MLN8237) plus vincristine plus rituximab is synthetic lethal and a potential curative therapy in aggressive B-cell non-Hodgkin lymphoma
    Daruka Mahadevan
    Arizona Cancer Center, The University of Arizona, Tucson, Arizona 85724, USA
    Clin Cancer Res 18:2210-9. 2012
    ..The addition of rituximab [R] to MV or MD was evaluated for synthetic lethality...
  6. pmc The c-Met receptor tyrosine kinase inhibitor MP470 radiosensitizes glioblastoma cells
    James W Welsh
    Departmentr of Radiation Oncology, The University of Texas M, d, Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, USA
    Radiat Oncol 4:69. 2009
    ..We hypothesized that inhibiting c-Met would decrease this protection and thus sensitize resistant tumor cells to the effects of radiation therapy...
  7. pmc MP470, a novel receptor tyrosine kinase inhibitor, in combination with Erlotinib inhibits the HER family/PI3K/Akt pathway and tumor growth in prostate cancer
    Wenqing Qi
    Arizona Cancer Center, The University of Arizona, Tucson, AZ 85724, USA
    BMC Cancer 9:142. 2009
    ..In this study, we evaluate whether MP470, a novel receptor tyrosine kinase inhibitor alone or in combination with Erlotinib has inhibitory effect on prostate cancer in vitro and in vivo...
  8. ncbi request reprint A novel tyrosine kinase switch is a mechanism of imatinib resistance in gastrointestinal stromal tumors
    D Mahadevan
    Arizona Cancer Center, Tucson, AZ 85724, USA
    Oncogene 26:3909-19. 2007
    ..MP470 synergizes with docetaxel (taxotere) and is cytotoxic to GIST cells...
  9. ncbi request reprint Transcriptosome and serum cytokine profiling of an atypical case of myelodysplastic syndrome with progression to acute myelogenous leukemia
    Daruka Mahadevan
    University of Arizona Cancer Center, Tucson, Arizona 85724, USA
    Am J Hematol 81:779-86. 2006
    ..Hence, a biomics approach has provided insight into elucidating disease mechanisms, molecular prognostic factors, and discovery of novel targets for therapeutic intervention...
  10. doi request reprint Phase I study of fixed dose gemcitabine plus epirubicin in patients with advanced solid malignancies
    Daruka Mahadevan
    Arizona Cancer Center, University of Arizona Health Sciences Center, Tucson, Arizona, USA
    Am J Clin Oncol 32:607-11. 2009
    ..The study was designed based on the hypothesis that prolonged exposure (over 90 minutes) may improve response rates and combination with epirubicin (EPI) is synergistic...
  11. ncbi request reprint Transcript profiling in peripheral T-cell lymphoma, not otherwise specified, and diffuse large B-cell lymphoma identifies distinct tumor profile signatures
    Daruka Mahadevan
    Department of Medicine, Arizona Cancer Center, University of Arizona, 1515 North Campbell Avenue, Tucson, AZ 85724, USA
    Mol Cancer Ther 4:1867-79. 2005
    ..This study illustrates the relevance of tumor-stroma immune trafficking and identified potential novel prognostic markers and targets for therapeutic intervention...
  12. ncbi request reprint Structure-based design of novel anti-cancer agents targeting aurora kinases
    Daruka Mahadevan
    Arizona Cancer Center, Division of Hematology Oncology and Division of Medicinal Chemistry, University of Arizona, 1515, N Campbell Avenue, Tucson, AZ 85724, USA
    Curr Med Chem Anticancer Agents 3:25-34. 2003
    ..In this review, we discuss the biology, rationale for targeting and approaches taken to inhibit this family of protein kinases, implicated in dysregulated chromosome segregation and cytokinesis...
  13. doi request reprint A phase I pharmacokinetic and pharmacodynamic study of AT7519, a cyclin-dependent kinase inhibitor in patients with refractory solid tumors
    D Mahadevan
    Arizona Cancer Center, Tucson, AZ 85724, USA
    Ann Oncol 22:2137-43. 2011
    ..Based on potent antitumor activity in preclinical models, a first-in-human clinical trial in refractory solid tumors investigated its safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD)...
  14. pmc Novel therapeutics for aggressive non-Hodgkin's lymphoma
    Daruka Mahadevan
    Arizona Cancer Center, Tucson, AZ, USA
    J Clin Oncol 29:1876-84. 2011
    ..Furthermore, we have developed the concept of a therapeutic signature using the 10 hallmarks of cancer, which may be incorporated into novel phase I/II drug development programs...
  15. ncbi request reprint Targeting the multidrug resistance-1 transporter in AML: molecular regulation and therapeutic strategies
    Daruka Mahadevan
    University of Arizona Cancer Center, Tucson, AZ 85724, USA
    Blood 104:1940-51. 2004
    ..Lessons learned from investigations of these and other mechanisms of cellular defense hold promise for a renaissance in the development of targeted therapeutics in acute leukemia...
  16. ncbi request reprint In vivo molecular pharmacology and antitumor activity of the targeted Akt inhibitor PX-316
    Emmanuelle J Meuillet
    Arizona Cancer Center, University of Arizona, Tucson, AZ 85724, USA
    Oncol Res 14:513-27. 2004
    ..Thus, PX-316 is the lead compound of a new class of potential agents that inhibit Akt survival signaling...
  17. pmc Discovery of a novel class of AKT pleckstrin homology domain inhibitors
    Daruka Mahadevan
    College of Medicine, Arizona Cancer Center, University of Arizona, Tucson, AZ 85721 0038, USA
    Mol Cancer Ther 7:2621-32. 2008
    ..These results show that these compounds are the first small molecules selectively targeting the PH domain of AKT...
  18. ncbi request reprint Targeting aurora2 kinase in oncogenesis: a structural bioinformatics approach to target validation and rational drug design
    Hariprasad Vankayalapati
    Arizona Cancer Center, University of Arizona, Tucson, Arizona 85724, USA
    Mol Cancer Ther 2:283-94. 2003
    ....
  19. ncbi request reprint A conserved glutamate residue in transmembrane helix 10 influences substrate specificity of rabbit OCT2 (SLC22A2)
    Xiaohong Zhang
    Department of Physiology, University of Arizona, Tucson, Arizona 85724, USA
    J Biol Chem 280:34813-22. 2005
    ..The results suggest that homology modeling offers an opportunity to direct future site-directed studies of OCT/substrate interaction...
  20. doi request reprint Phase I pharmacokinetic and pharmacodynamic study of the pan-PI3K/mTORC vascular targeted pro-drug SF1126 in patients with advanced solid tumours and B-cell malignancies
    D Mahadevan
    University of Arizona Cancer Center, Tucson, AZ, USA
    Eur J Cancer 48:3319-27. 2012
    ..A first-in-human study evaluated safety, dose limiting toxicities (DLT), maximum tolerated dose (MTD), pharmacokinetics (PK), pharmacodynamics (PD) and efficacy of SF1126, in patients with advanced solid and B-cell malignancies...
  21. ncbi request reprint Strategies for targeting the multidrug resistance-1 (MDR1)/P-gp transporter in human malignancies
    Daruka Mahadevan
    University of Arizona Cancer Center, Tucson, AZ 85724, USA dmahadevan azcc arizona edu
    Curr Cancer Drug Targets 5:445-55. 2005
    ....
  22. ncbi request reprint Identification of a lead small-molecule inhibitor of the Aurora kinases using a structure-assisted, fragment-based approach
    Steven L Warner
    College of Pharmacy, University of Arizona, Tucson, Arizona, USA
    Mol Cancer Ther 5:1764-73. 2006
    ..Although biological effects were observed only at relatively high concentrations, this chemical series provides an excellent starting point for drug optimization and further development...
  23. doi request reprint NSC348884, a nucleophosmin inhibitor disrupts oligomer formation and induces apoptosis in human cancer cells
    W Qi
    Arizona Cancer Center, University of Arizona, Tucson, AZ 85724, USA
    Oncogene 27:4210-20. 2008
    ..The data together show that NSC348884 is an SMI of NPM oligomer formation, upregulates p53, induces apoptosis and synergizes with chemotherapy. Hence, an SMI to NPM may be a useful approach to anticancer therapy...
  24. ncbi request reprint Modulation of ligand binding by alternative splicing of the alphaPS2 integrin subunit
    Thomas A Bunch
    Department of Molecular and Cellular Biology, Arizona Cancer Center, 1515 N Campbell Ave, Tucson, Arizona 85724, USA
    J Cell Biochem 102:211-23. 2007
    ..These results may have relevance for vertebrate alpha6 and alpha7, which are alternatively spliced at the same site...
  25. pmc An orally active small molecule TGF-beta receptor I antagonist inhibits the growth of metastatic murine breast cancer
    Matthew P Rausch
    Department of Immunobiology, University of Arizona, Tucson, AZ 85724, USA
    Anticancer Res 29:2099-109. 2009
    ..The purpose of this study was to investigate the efficacy of SM16, a novel small molecule ALK5 kinase inhibitor, to treat a highly metastatic, TGF-beta-producing murine mammary carcinoma (4T1)...
  26. ncbi request reprint Thioredoxin-1 binds to the C2 domain of PTEN inhibiting PTEN's lipid phosphatase activity and membrane binding: a mechanism for the functional loss of PTEN's tumor suppressor activity
    Emmanuelle J Meuillet
    Arizona Cancer Center, University of Arizona, 1515 N Campbell Blvd, Tucson, AZ 85724, USA
    Arch Biochem Biophys 429:123-33. 2004
    ..The results of the study suggest that the increased levels of Trx-1 in human tumors could lead to functional inhibition of PTEN tumor suppressor activity providing an additional mechanism for tumorigenesis with loss of PTEN activity...
  27. ncbi request reprint Specific inhibition of the Akt1 pleckstrin homology domain by D-3-deoxy-phosphatidyl-myo-inositol analogues
    Emmanuelle J Meuillet
    Arizona Cancer Center, University of Arizona, Tucson, Arizona 85724, USA
    Mol Cancer Ther 2:389-99. 2003
    ..This study shows that the DPIs are a novel class of growth inhibitory agents with a novel mechanism of action through binding to the PH domain of Akt and inhibition of Akt activation...
  28. ncbi request reprint Amino acid changes in Drosophila alphaPS2betaPS integrins that affect ligand affinity
    Thomas A Bunch
    Department of Molecular and Cellular Biology, Arizona Cancer Center, Tucson, Arizona 85724, USA
    J Biol Chem 281:5050-7. 2006
    ..These studies establish a means to evaluate mechanisms and consequences of integrin affinity modulation in a tractable model genetic system...
  29. pmc Aurora inhibitor MLN8237 in combination with docetaxel enhances apoptosis and anti-tumor activity in mantle cell lymphoma
    Wenqing Qi
    Arizona Cancer Center, University of Arizona, 1515 N Campbell Avenue, Tucson, AZ 85724, USA
    Biochem Pharmacol 81:881-90. 2011
    ..Together, our results suggest that MLN8237 plus docetaxel may represent a novel therapeutic strategy that could be evaluated in early phase trials in relapsed/refractory aggressive B-cell NHL...
  30. ncbi request reprint Monoclonal antibody therapies targeting pancreatic ductal adenocarcinoma
    Kevin Engelhardt
    Arizona Cancer Center, Tucson, AZ 85724, USA
    Curr Drug Discov Technol 3:231-43. 2006
    ....
  31. pmc Design and activity of a murine and humanized anti-CEACAM6 single-chain variable fragment in the treatment of pancreatic cancer
    Christopher J Riley
    Arizona Cancer Center, Tucson, AZ 85724, USA
    Cancer Res 69:1933-40. 2009
    ..Collectively, our results have important implications for the development of novel antibody-based therapies against CEACAM6 in PDA...
  32. doi request reprint Translational advances and novel therapies for pancreatic ductal adenocarcinoma: hope or hype?
    Sreenivasa Chandana
    Michigan State University, Department of Medicine, East Lansing, MI, USA
    Expert Rev Mol Med 11:e34. 2009
    ..Here we summarise current knowledge and areas where the field is advancing, and give our opinion on the research direction the field should be focusing on to better deliver promising therapies for our patients...
  33. doi request reprint Variation in cytotoxic T-lymphocyte responses to peptides derived from tyrosinase-related protein-2
    Cheryl E Myers
    Department of Immunobiology, University of Arizona, Life Sciences North, Tucson, AZ 85724, USA
    Hum Immunol 69:24-31. 2008
    ..Our results may partially explain why some patients have better clinical responses to peptide-based immunotherapy, whereas others respond poorly...
  34. ncbi request reprint Actin microfilament aggregation induced by withaferin A is mediated by annexin II
    Ryan R Falsey
    Nat Chem Biol 2:33-8. 2006
    ....
  35. ncbi request reprint Will MDR-1/P-gp modulators provide clinical benefit in hematologic malignancies?
    Daruka Mahadevan
    Leuk Res 30:1077-8. 2006
  36. ncbi request reprint Mapping of the active site of glutamate carboxypeptidase II by site-directed mutagenesis
    Petra Mlcochova
    Gilead Sciences and IOCB Research Centre, Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic, Prague, Czech Republic
    FEBS J 274:4731-41. 2007
    ....
  37. ncbi request reprint Efficacy of lenalidomide in myelodysplastic syndromes
    Alan List
    Department of Interdisciplinary Oncology, University of South Florida and the H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612 9497, USA
    N Engl J Med 352:549-57. 2005
    ..In patients with myelodysplastic syndromes and symptomatic anemia, we evaluated the safety and hematologic activity of lenalidomide, a novel analogue of thalidomide...